2026年10月16日星期五
M
Küresel Panorama
Küresel haberler
[Comment] Establishing cardiovascular safety of the small-molecule GLP-1 receptor agonist orforglipron in type 2 diabetes— 柳叶刀 Lancet[Comment] Making every vial count: fractional dosing of yellow fever vaccine— 柳叶刀 Lancet[Comment] Shortening treatment to accelerate hepatitis C elimination— 柳叶刀 Lancet[Comment] Offline: In praise of astrologers, sorcerers, and magicians— 柳叶刀 Lancet[World Report] “You have to be willing to take risks”: the 2026 Nobel prizes— 柳叶刀 Lancet[World Report] Health in Brazil's election— 柳叶刀 Lancet[Perspectives] Shadows and interiority— 柳叶刀 Lancet[Perspectives] Beyond the battlefield: war and global health security— 柳叶刀 Lancet[Comment] Establishing cardiovascular safety of the small-molecule GLP-1 receptor agonist orforglipron in type 2 diabetes— 柳叶刀 Lancet[Comment] Making every vial count: fractional dosing of yellow fever vaccine— 柳叶刀 Lancet[Comment] Shortening treatment to accelerate hepatitis C elimination— 柳叶刀 Lancet[Comment] Offline: In praise of astrologers, sorcerers, and magicians— 柳叶刀 Lancet[World Report] “You have to be willing to take risks”: the 2026 Nobel prizes— 柳叶刀 Lancet[World Report] Health in Brazil's election— 柳叶刀 Lancet[Perspectives] Shadows and interiority— 柳叶刀 Lancet[Perspectives] Beyond the battlefield: war and global health security— 柳叶刀 Lancet

Global pharma firms walk back innovative drug investments in Japan

Kaynak 日经 Nikkei Asia2 saat önce
İçerik özeti

Global pharma firms walk back innovative drug investments in Japan

Bu site yalnızca başlık ve özet dizini sunar; tam içerik ve telif hakkı asıl yayıncıya aittir, lütfen okumak için orijinal bağlantıya tıklayın.

Orijinal metne git
Ait olduğu kanal
Finans
Ait olduğu bölge
Japonya
Orijinal dil
English
Kayıt numarası
business-839627c8

Comments 0 comments

No comments yet. Be the first.

Global pharma firms walk back innovative drug investments in Japan · Küresel Panorama